Hikma Pharmaceuticals (HKMPF) Financial Statements
Hikma Pharmaceuticals Financial Overview
Hikma Pharmaceuticals's market cap is currently $4.80B. The company's EPS TTM is $1.79; its P/E ratio is 12.95; and it has a dividend yield of 3.73%. Hikma Pharmaceuticals is estimated to report earnings on February 25, 2027, and the estimated EPS forecast is $1.13. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 3.35B | $ 3.13B | $ 2.88B | $ 2.52B | $ 2.55B |
| Gross Profit | $ 1.44B | $ 1.42B | $ 1.41B | $ 1.26B | $ 1.30B |
| Operating Income | $ 579.92M | $ 612.00M | $ 367.00M | $ 591.00M | $ 634.00M |
| EBITDA | $ 845.00M | $ 805.56M | $ 817.00M | $ 485.00M | $ 767.78M |
| Net Income | $ 410.43M | $ 359.00M | $ 190.00M | $ 188.00M | $ 421.00M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 354.13M | $ 213.00M | $ 229.00M | $ 292.00M | $ 450.00M |
| Total Assets | $ 5.67B | $ 5.13B | $ 4.68B | $ 4.47B | $ 4.37B |
| Total Debt | $ 1.60B | $ 1.31B | $ 1.19B | $ 1.28B | $ 846.00M |
| Net Debt | $ 1.28B | $ 1.12B | $ 986.00M | $ 1.01B | $ 420.00M |
| Total Liabilities | $ 3.07B | $ 2.81B | $ 2.47B | $ 2.32B | $ 1.91B |
| Stockholders' Equity | $ 2.59B | $ 2.31B | $ 2.20B | $ 2.13B | $ 2.45B |
| Cash Flow | |||||
| Free Cash Flow | $ 165.40M | $ 399.00M | $ 439.00M | $ 392.00M | $ 493.00M |
| Operating Cash Flow | $ 366.53M | $ 564.00M | $ 608.00M | $ 530.00M | $ 638.00M |
| Investing Cash Flow | $ -402.27M | $ -381.00M | $ -333.00M | $ -607.00M | $ -238.00M |
| Financing Cash Flow | $ 59.22M | $ -188.00M | $ -337.00M | $ -58.00M | $ -287.00M |
Currency in USD
